Staff

Contact details

Previous articles

University of Cambridge portfolio firms raise more than £30m in 10 months

Xaar says trading back on track after customers' import duty issues in China

Briefs: Antitope signs deal with NKT Therapeutics, Amino, Optibase integrate set top IPTV boxes

Minster Pharma grows R&D spend in ‘06/07 as momentum in clinical trials builds

Domino Printing says sales up as expected; strong in Asia, Europe 'more difficult'

Screen Technology gears up for full scale production; sees no need to raise more cash

At last, the stock market buys into CSR's vision of an integrated future

Plasmon’s restructure at ‘advanced stage’; flags £3.7m one-off loss, ’07 pre-tax loss of £15m ahead of share placment

Amino’s 08 pretax profit grows 53% despite flat revenue as new technology, stronger dollar deliver higher margins

ARM beats market with 31% jump in Q1 pre-tax profit as demand strong across portfolio

Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com

Corporate profiles

 • Cambridge Biostability

Paul Rewrie Commercial & Operations Director

Cambridge Biostability Ltd is a privately held company founded in 1998 with a combination of investor funding and project financing. It has a portfolio of patents and is entering into a number of agreements to licence and provide outsourced production of thermo-stable liquid vaccines and drugs. Development

[Cambridge Biostability's profile]

Top20 Index

Currently: 159.05